LumaCyte, Inc.

Founded in 2012 and based in Virginia, US, LumaCyte, Inc. operates as a pharmaceutical manufacturing company that develops laser force cytology (LFC) and multivariate analysis tools used for single cell sorting and analysis. In September 2023, LumaCyte, Inc. raised Series B funding from Malvern Instruments Ltd.

As of 2023, Sean Hart serves as the CEO and CSO of the company. The company's flagship product, the radiance laser force cytology™ (LFC™) analysis platform, is a real-time cell analyzer designed to deliver single-cell results. Radiance finds its utility in fields such as vaccine development, biomanufacturing, cell therapy, gene therapy, and infectious disease research. The firm also offers a comprehensive software suite called Illuminate, designed to integrate with modern laboratory procedures, including instrument, analyzer, and sampler applications, empowering researchers with data analysis and instrument control capabilities.

In addition, LumaCyte provides ReportR™, a cloud-based cell analysis software platform that delivers data analysis, allowing researchers to visualize data and trends, speeding up the development of customized methods. The company’s multivariate analysis tool measures parameters that reflect the intrinsic biophysical and biochemical properties of cells. The organization plans to use the September 2023 funding to support the expansion of its geographic reach.